Introduction: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) are the first-line standard of care for patients with advanced non-small-cell lung cancer (NSCLC) harboring EGFR mutations. Rates of serious adverse events are lower with EGFR-TKIs than other drugs. However, some reports have described EGFR-TKI-associated cardiac dysfunction, but the underlying mechanism is currently unclear. Case: A 72-year-old women presented with non-sustained ventricular tachycardia (NSVT) associated with EGFR-TKI. Because the voltage map detected a low voltage area in the right ventricle, ablation was performed. Conclusion: In this patient, NSVT resolved after ablation, and EGFR-TKI could then be readministered at the original dose.